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Swiss mice were injected intraperitoneally with uninfected or human immunodeficiency virus type 1 (HIV-1) infected human U937 cells. At 6 days, no residual human cells were detected in mouse tissues as determined by PCR analysis of DNAs from injected mice using primers and probes for the human HLA-DQ alpha gene. At 6 to 12 months, approximately 60% of the HIV-l-injected mice had antibodies to HIV-1 gp 120 and gp41 proteins. Fifteen percent of the animals showed evidence of HIV-1 infection as determined by PCR analyses of DNA from peripheral blood leukocytes and by in situ hybridization for detection of HIV-1 mRNA in peritoneal cells. In this set of experiments, spleen cells from mice sacrificed at different times after injection were cultured for 48 h in the presence or absence of mitogens [i.e. : concanavalin (Con A) or anti-CD3 antibody] and then tested for lymphocyte proliferation. At 10 to 12 months, splenocytes from approximately 80 % of Swiss mice injected with HIV-l-infected U937 cells exhibited a marked defect in their proliferative response to Con A or anti-CD3 antibody as compared with spleen cells from both uninjected or U937 cell-injected mice. Similar results were obtained at 12 months in C3H/HeJ mice. Non-responding spleen cells from HIV-l-injected Swiss mice did not proliferate in response to anti-CD3 antibody even in the presence of co-stimulatory molecules such as phorbol myristate acetate or anti-CD28 antibody. Splenocytes from these mice also exhibited an impaired capacity to produce interferon-y and interleukin-4 after mitogen stimulation. No T cell defects were observed in control-injected mice. Immunofluorescence analyses revealed a significant decrease in the percentage of both CD4 ÷ and CD8 + spleen cells in HIV-l-injected mice. These data indicate that immunocompetent mice can be used to investigate some HIV-1-related immune dysfunctions in vivo.
Although human immunodeficiency virus type 1 (HIV-1) is recognized as the aetiologic agent of AIDS (BarreSinoussi et al., 1983; Coffin et al., 1986; Popovic et al., 1984) , several aspects concerning the relationship between HIV-1 infection and AIDS are still unclear. The use of animal models of HIV-1 infection is an essential step for understanding the pathogenesis of HIV-1-induced immunodeficiency and defining effective antiviral therapies and vaccines (Gardner & Luciw, 1989) . In particular, the mouse, as a small and well-characterized laboratory animal, would be particularly useful (Ruprecht et al., 1992) . As it was assumed that the mouse could not be directly infected by HIV-1, most current approaches for the study of HIV-1-specific effects in the mouse have involved either the transplantation of t We dedicate this article to the memory of our colleague and friend Professor Giovanni B. Rossi, who died on 20 February 1994. immunodeficient nude mice with human cells (Namikawa et al., 1988; Mosier et al., 1991 ; Puddu et al., 1991) or the use of mice transgenic for HIV-1 genomes (Leonard et aL, 1988; Vogel et al., 1988) . However these approaches do not permit an investigation of possible T cell alterations induced by HIV-1 in an immunocompetent host.
We have recently reported that persistent HIV-1 infection can be established in some normal mice approximately 1 year after intraperitoneal (i.p.) injection with HIV-l-infected U937 cells (Locardi et al., 1992) . In this study, we have investigated in detail the immunological response of mice to the injection of HIV-1-infected U937 cells.
The human histiocytic lymphoma cell line U937 (Sunstrom & Nilsson, 1987) was cultured in RPMI medium supplemented with 10 % heat-inactivated fetal calf serum (FCS). U937 cells were infected with HIV-1 (IIIB strain) as previously described (Locardi et al., 0001-2501 © 1994 SGM Short communication Evaluation of the presence of antibodies to HIV-1 gpl20 and gp41 peptides in control untreated mice and in mice injected with either uninfected or HIV-l-infected U937 cells. Peptides were synthesized by an ABI 431A peptide synthesizer. Amino acid sequences of BH10 HIV-1 env-encoded synthetic peptides were the following: gpl20 peptide, CNNTRKSIRIQRGPGRAFVTIGKIG, amino acids 308 to 331, encompassing the principal neutralizing domain in the gpl20 protein of BH10 clone (Ratner et al., 1985) ; gp41 peptide, ERYLKDQQLLGIWGCSGKLIC, amino acids 591 to 611, representing a highly immunodominant epitope in the gp41 protein (Wang et al., 1986) . The ELISA was performed as previously described (Kenealy et al., 1989) , with slight modifications. Briefly, synthetic peptides were immobilized on Maxi Sorp (Nunc) microtitre plates by an overnight incubation at 4 °C with the peptide solution (100 Bl/well; 2 ~tg/ml in water). Mouse sera (diluted 1:50) were added and incubated for 90 rain at room temperature. Subsequently, wells were incubated with peroxidase-labelled goat anti-mouse IgG (Sigma) for 1 h at room temperature. Finally, binding was revealed by reading the A4s 0 values after a 15 rain incubation at room temperature with o-phenylenediamine as a substrate. Values represent the mean adsorbance value of each individual serum tested in duplicate. The cut-off value was calculated as follows: mean adsorbance value of all the control sera (from both untreated and cell-injected mice) + 3 S.D. Sera showing A405 values higher than this threshold were considered positive for anti-HIV-1 antibodies.
1990). Chronically HIV-l-infected U937 cells produced large amounts of HIV-1 in vitro (Locardi et al., 1990) , as well as in vivo when transplanted subcutaneously in nude mice treated with antibodies to interferon (IFN)-e/fl (Puddu et al., 1991) . Five-week-old male Swiss mice (Charles River) were injected i.p. with 0.5 ml of 4% thioglycolate broth. Four days later, mice were inoculated i.p. with 2 x l0 G to 4 x 10 ~ of either HIV-l-infected U937 cells or uninfected U937 cells (control-injected group). Other mice were left untreated (control-untreated group). All groups of mice were kept under special biosafety level 3 conditions, using sterilized materials during the course of the experiments, as previously described (Locardi et al., 1992) . Injection of Swiss mice with HIV-1-infected U937 cells resulted in a very rapid elimination of virus-infected human cells. At 6 days, human DNA sequences were not detected, by PCR analysis, in DNAs extracted from spleens, lymph nodes and peritoneal cells from mice injected with HIV-l-infected U937 cells (data not shown), using primers and probes for the HLA-DQ alpha gene (Locardi et al., 1992) . The sensitivity of our PCR technique was such as to detect as few as 10 human cells mixed with 2 x 106 mouse peritoneal cells.
Using specific ELISAs with gpl20 V3 IIIB and gp4l peptides, we determined the presence of anti-HIV-1 antibodies at different times after injection of either uninfected or HIV-l-infected U937 cells. Anti-HIV-1 antibodies were not detected in any of the HIV-1-injected mice at 1 month. However at 3 months, 22 of 55 HIV-1-injected mice tested had anti-gpl20 antibodies and 14 of 30 mice had antibodies to gp41 ( Fig. 1) . At 6 months, anti-HIV-1 gpl20 antibodies were detected in 39 of 64 HIV-l-injected mice, while anti-gp41 antibodies were found in 20 of 30 mice ( Fig. 1) . High levels of anti-gpl20 antibodies were maintained at 10 to 12 months in approximately 60% of the HIV-l-injected mice (not shown). In contrast, none of the sera from mice injected with uninfected U937 cells showed any evidence of antigpl20 or anti-gp41 antibodies at any time after injection ( Fig. 1) . At 10 months, sera from mice injected with HIV-1-infected U937 cells exhibited levels of mouse IgG similar to those found in control mice injected with uninfected U937 cells (240 +_ 60 mg/ml versus 235+ * Single cell suspensions prepared from the spleen of each mouse were washed in RPMI medium, centrifuged, suspended in 10% DMSO and 90% FCS in 2 ml cryotubes (Nunc) at about 2 x 107 cells/tube and frozen at -80 °C in liquid nitrogen until testing. At the time of each experiment, equal numbers of vials from mice injected with HIV-l-infected U937 cells or control mice were thawed. Cell suspensions were extensively washed, viable cells were determined by trypan blue dye exclusion and resuspended at 1 x 106 cells/ml in RPMI 1640 medium (Flow) containing 10% FCS, 2 mM-glutamine, 25 mM-HEPES, 50 gM-2-mercaptoethanol, penicillin (50 IU/ml), streptomycin (50 gg/ml), sodium pyruvate (0.11 mg/ml) and nonessential amino acids and cultured alone or in the presence of Con A (2 gg/ml) (Sigma) or anti-CD3 MAb (Massaro et al., 1990) . Spleen cell proliferation was measured in triplicate 0.2 ml cultures using 96-well plates. Plates were incubated in 5 % CO s at 37 °C and harvested on day 2, 18 h after addition of 0"5 gCi of [] ND, Not determined; NS, not significant. ,<. 0.01, ~< 0.001 represents P (one-tailed Student's t-test).
68 mg/ml, respectively), as determined by using a mouse IgG quantitative immunodiffusion kit (ICN, Flow; . At 6 months, DNAs from peripheral blood mononuclear cells of 26 HIV-l-injected mice were extracted and analysed for the presence of HIV-1-specific sequences by PCR analysis using pairs of primers specific for HIV-1 env and gag sequences (Locardi et al., 1992) . Likewise, peritoneal cells from the same mice were tested for the presence of specific HIV-1 mRNAs by in situ hybridization using a 35S-labelled HIV-1 probe (Dupont-NEN) as described elsewhere (Harper et al., 1986) . At this time, four of 26 of HIV-l-injected mice showed evidence of HIV-1 infection as determined by DNA PCR analyses, as well as by in situ hybridization techniques for detection of specific HIV-1 mRNAs in peritoneal cells (data not shown). Similar results were obtained by examining HIV-l-injected mice sacrificed at 10 to 12 months. The frequency of HIV-l-positive cells was very low, approximately one in 10 000 cells.
In this set of experiments, we determined whether HIV-l-injected Swiss mice could develop any specific defect in the response of their spleen cells to T cell mitogens. At 1, 3, 6, 10 and 12 months, mice in each group were sacrificed and their spleen cells cultured for 48 h in the presence or absence of mitogens, which were then tested for lymphocyte proliferation. At 1 and 3 months, spleen cells from HIV-1-injected mice exhibited a proliferative response to mitogens identical to that of spleen cells from both groups of control mice (not shown). At 6 months, the extent of [3H]thymidine incorporation after concanavalin A (Con A) stimulation was significantly lower in spleen cells from HIV-1-injected mice than in corresponding cultures of spleen cells from both groups of control mice. At 12 months, splenocytes from HIV-l-injected mice showed a marked defect in their proliferative response to both Con A and anti-CD3 antibody (Table 1 , experiment 1). In a second experiment using Swiss mice, no difference was observed at 6 months, but at 10 months there was again a marked difference in the response to both Con A and anti-CD3 antibody of splenocytes from mice injected with HIV-1-infected U937 cells compared with control spleen cultures ( Table 1, cell response to mitogens was also observed in C3H/HeJ mice at 12 months after injection of HIV-l-infected cells (Table 1 , experiment 3). No significant differences were observed between the proliferative responses to either Con A or anti-CD3 antibody by spleen cells from untreated or control U937 cell-injected mice. By evaluating the total number of HIV-l-injected mice responding at 10 to 12 months to each of the mitogens, only nine of 37 mice responded to Con A and 10 of 38 mice responded to anti-CD3 antibody, compared with 37 of 38 mice in the control groups responding to Con A and all of 31 control mice responding to anti-CD3. To determine whether it was possible to restore the proliferative response of spleen cells from mice injected with HIV-l-infected U937 cells, we added other costimulatory molecules together with the T cell mitogen. In preliminary experiments, we found that the simultaneous addition of phorbol myristate acetate (PMA) and anti-CD28 antibody was more effective than PMA and calcium ionophore in inducing T cell proliferation (not shown). Fig. 2 illustrates the results obtained with splenocytes from 11 HIV-l-injected and two representative control mice. In cultures from both control mice, the simultaneous addition of either PMA or anti-CD28 antibody to anti-CD3-treated cells induced a slight increase in [3H]thymidine incorporation as compared with cultures treated with anti-CD3 alone. Two different patterns of response were found in spleen cell cultures from HIV-1-injected mice. First, in eight non-responding splenocytes cultures, no proliferation was observed even after addition of either PMA or anti-CD28 antibody to anti-CD3-treated cells. Second, in partially responding cell cultures from three mice, there was an increase of [3H]thymidine incorporation after the addition of these co-stimulatory factors to anti-CD3-treated cells, comparable to the increase in the control cultures (Fig. 2) . In these cultures, a proliferative response was also found by combining PMA and anti-CD28-antibody, whereas the single treatments were ineffective (not shown).
We then evaluated whether spleen cells from HIV-1-injected mice exhibited an altered pattern of cytokine production, by measuring IFN-v and interleukins 4 and 6 (IL-4 and IL-6) in the supernatants of stimulated spleen cells using specific ELISAs. At 12 months, Con A-treated spleen cells from HIV-l-injected mice released lower amounts of both IFN-7 and IL-4 than the stimulated cultures from both groups of control mice (Table 2) . There was a direct correlation between IFN-? or IL-4 production and the proliferative response to Con A. In particular, IFN-~ or IL-4 released by the spleen cells non-responsive to Con A could barely be detected, whereas high levels were secreted by normally responding spleen cells (not shown). No significant differences in the production of IL-6 were detected in splenocyte cultures from the three groups of mice.
Immunofluorescence analysis of the spleen cell populations from mice injected with U937 cells and with HIV-l-infected U937 cells was then performed by using fluorescein isothiocyanate (FITC)-conjugated monoclonal antibodies (MAbs) to specific membrane antigens. At 12 months, spleen cells from HIV-l-injected mice showed a decrease in the percentage of CD4 + and CD8 + cells as compared with control mice (28"5 % to 18 % and 9.1% to 6.4 %, respectively). There was also a reduction in the percentage of B cells, whereas no significant difference in the percentage of Mac-1 + cells was detected (Table 3) .
The most remarkable finding reported in this article is the dramatic and progressive impairment of splenic T cell functions observed in mice injected with HIV-l-infected U937 cells. At 10 to 12 months, the functional anergy of spleen cells to Con A or anti-CD3-antibody was consistently found in two different experiments with Swiss mice and in one experiment with C3H/HeJ mice (Table 1) . This anergy was manifest not only to Con A and anti-CD3 antibody but also when co-stimulatory molecules such as PMA or anti-CD28 were added (Fig. * Swiss mice were sacrificed at 12 months after inoculation of uninfected U937 cells or HIV-l-infected U937 cells. Spleen cells were seeded at 1 x 106 cells/ml in 24-well plates. Cells were cultured in medium alone or in the presence of Con A (2 ~tg/ml) or LPS (10 ~tg/ml). Cell supernatants were harvested after 3 days of culture and then tested for cytokine production by ELISAs specific for IFN-y (Genzime), IL-4 (Endogen) and IL-6 (Endogen). Values represent the S.E.M. of cytokine production (pg/ml).
t NS, Not significant. :~ P < 0-007 (one-tailed Student's t-test). 28"5+2'3 9"1+1"0 62"9+4'1 4'8+1"6 (10) (10) (10) (5) HIV-l-infected U937
18"0+ 1-9 6.4+0-5 51'2+2-1 4.8+0-7 (24) (24) (24) (6) P valuer 0.005 0'007 0.008 0.982 * Mice were sacrificed 12 months after U937 cell injection. Spleen cells (106) were incubated in 100 lal of FITC-conjugated antibody diluted in PBS containing sodium azide, 0"1% (w/v) and BSA, 0.1% (w/v). After 30 min at 4 °C, the cells were washed and fixed with 2 % formaldehyde. The following FITC-conjugated antibodies were used: anti-L3T4/CD4, anti-Ly-2/CD8, anti-Mac-1/CDllb (Boehringer Mannheim Biochemica) and anti-IgG (heavy and light chains; BioSys). Fixed cells were analysed by flow cytometry (FACScan; Becton Dickinson).
t One-tailed Student's t-test.
2). Furthermore, the spleen cells taken from Swiss mice 12 months after inoculation of HIV-1-infected U937 cells produced much less IFN-), and IL-4 (but not IL-6) after stimulation with Con A or anti-CD3, than the spleen cells from the two groups of control mice (Table 2) . At 12 months, an approximate 30 % reduction in the percentage of CD4 + and CD8 ÷ cells was observed in the spleen cell populations from these mice as compared with control mice (Table 3) . However this finding cannot explain the anergy as in several instances spleen cells with a normal percentage of CD4 + and CD8 + cells from HIV-1-injected mice did not proliferate after incubation with T cell mitogens.
It is noteworthy that at 12 months, approximately 80% of the HIV-l-injected mice revealed a complete defect in the proliferative response of their spleen cells to Con A or anti-CD3 antibody, a percentage largely exceeding that of mice exhibiting HIV-l-specific sequences. We were unable, therefore, to obtain clear-cut evidence of HIV-1 infection in a large number of mice exhibiting a suppression of T cell functions. This finding suggests that the defective T cell response to mitogens does not necessarily reflect persistent HIV-1 infection. Therefore, mechanisms other than those involving a direct killing of T cells by HIV-1 may be responsible for the T cell defects observed. Some HIV-1 proteins exhibit amino acid homology with human cellular proteins involved in the immune response and antibodies to these proteins might inhibit T cell proliferation (Golding et al., 1989) . Antibodies to viral/cellular epitopes can be produced by B cells even after the clearance of the aetiological viral agent (Oldstone, 1987) . Thus, we can hypothesize that even a temporary exposure of mice to HIV-1 could induce the development of an autoimmune response, resulting in T cell anergy. It is also possible that HIV-1 can activate an endogenous retrovirus or induce the expression of an endogenous retroviral protein that may prove immunosuppressive (Krieg et al., 1992) .
Although the mechanisms involved in these HIV-Iinduced immunological alterations are not evident at present, it is of interest to us that the functional T cell defects so characteristic of human HIV-1 infection were the only cellular dysfunction we have detected to date. No significant alterations in the percentage of Mac-1 + spleen cells were observed (Table 3 ) and peritoneal macrophages from both HIV-1-injected and control mice released similar amounts of lipopolysaccharide (LPS)-induced cytokines such as tumour necrosis factor-~ and IL-6 (not shown).
To understand the pathogenesis of AIDS in HIV-1-infected patients, it is essential to clarify the mechanisms involved in the depression of T cell functions in these patients Lane et al., 1985; Miedema et al., 1988 ) and animal models may provide important insights in defining these mechanisms (Gardner & Luciw, 1989) . The data reported herein demonstrate, for the first time, that it is possible to induce a progressive suppression of T cell function in normal immunocompetent mice by injecting HIV-l-infected cells. Although it is still unclear whether these findings can be relevant to HIV-1 infection in patients, we suggest that normal mice injected with HIV-l-infected human cells may represent a useful approach for investigating some aspects of the HIV-l-related immune dysfunctions in vivo.
